{"id":37321,"date":"2011-01-26T00:00:00","date_gmt":"2011-01-25T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/"},"modified":"2020-11-16T16:15:53","modified_gmt":"2020-11-16T15:15:53","slug":"ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/","title":{"rendered":"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen"},"content":{"rendered":"<p>Esta ser\u00e1 la primera desinversi\u00f3n que lleva a cabo Ysios, que hace 14 meses particip\u00f3 junto a otros cuatro inversores internacionales \u2013 Morningside Venture, MVM Life Science Partners, Ventech y Sectoral Asset Management \u2013 en la ronda financiaci\u00f3n de BioVex de 70 millones de d\u00f3lares. En esta operaci\u00f3n tambi\u00e9n invirtieron los inversores especializados que ya estaban presentes en la compa\u00f1\u00eda, entre los que se encontraban Forbion, Scottish Equity Partners, Credit Agricole Private Equity y otros inversores americanos. <\/p>\n<p> La inversi\u00f3n en BioVex fue la tercera inversi\u00f3n de Ysios BioFund I, constituido en agosto de 2008 y que cuenta con un patrimonio de 69 millones de euros. Posteriormente, Ysios ha invertido en Cardoz, compa\u00f1\u00eda sueca especializada en el tratamiento de enfermedades cardiovasculares con un componente inflamatorio, y en Sabirmedical, empresa espa\u00f1ola de tecnolog\u00eda m\u00e9dica especializada en sistemas de monitorizaci\u00f3n no invasiva de diversas patolog\u00edas, que forma parte de la Bioincubadora unicada en el Parc Cient\u00edfic Barcelona. Adem\u00e1s, Ysios posee participaciones en la biofarmac\u00e9utica espa\u00f1ola Cellerix, especializada en terapia celular, y en la empresa suiza Endosense, desarrolladora de tecnolog\u00edas y dispositivos m\u00e9dicos que mejoran la eficacia y la seguridad en el uso de cat\u00e9teres en el tratamiento de arritmias card\u00edacas.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La gestora espanyola de sociedades de capital riesgo Ysios Capital Partners, ubicada en el parc Cient\u00edfic Barcelona (PCB), realizar\u00e1 su primera desinversi\u00f3n con la venta de la participaci\u00f3n de su fondo Ysios BioFund I en BioVex, al acordarse la adquisici\u00f3n del 100% de la compa\u00f1\u00eda estadounidense por parte de Amgen, una de las mayores empresas biotecnol\u00f3gicas del mundo, por un total de 1.000 millones de d\u00f3lares. BioVex tiene actualmente dos compuestos biol\u00f3gicos en desarrollo cl\u00ednico: OncoVex, una nueva vacuna oncol\u00edtica que podr\u00eda representar una nueva estrategia para el tratamiento del melanoma y otros tumores s\u00f3lidos, e ImmunoVex, una vacuna para el herpes genital.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-37321","post","type-post","status-publish","format-standard","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La gestora espanyola de sociedades de capital riesgo Ysios Capital Partners, ubicada en el parc Cient\u00edfic Barcelona (PCB), realizar\u00e1 su primera desinversi\u00f3n con la venta de la participaci\u00f3n de su fondo Ysios BioFund I en BioVex, al acordarse la adquisici\u00f3n del 100% de la compa\u00f1\u00eda estadounidense por parte de Amgen, una de las mayores empresas biotecnol\u00f3gicas del mundo, por un total de 1.000 millones de d\u00f3lares. BioVex tiene actualmente dos compuestos biol\u00f3gicos en desarrollo cl\u00ednico: OncoVex, una nueva vacuna oncol\u00edtica que podr\u00eda representar una nueva estrategia para el tratamiento del melanoma y otros tumores s\u00f3lidos, e ImmunoVex, una vacuna para el herpes genital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2011-01-25T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:15:53+00:00\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen\",\"datePublished\":\"2011-01-25T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:15:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/\"},\"wordCount\":225,\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/\",\"name\":\"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"datePublished\":\"2011-01-25T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:15:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/","og_locale":"es_ES","og_type":"article","og_title":"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen - Parc Cient\u00edfic de Barcelona","og_description":"La gestora espanyola de sociedades de capital riesgo Ysios Capital Partners, ubicada en el parc Cient\u00edfic Barcelona (PCB), realizar\u00e1 su primera desinversi\u00f3n con la venta de la participaci\u00f3n de su fondo Ysios BioFund I en BioVex, al acordarse la adquisici\u00f3n del 100% de la compa\u00f1\u00eda estadounidense por parte de Amgen, una de las mayores empresas biotecnol\u00f3gicas del mundo, por un total de 1.000 millones de d\u00f3lares. BioVex tiene actualmente dos compuestos biol\u00f3gicos en desarrollo cl\u00ednico: OncoVex, una nueva vacuna oncol\u00edtica que podr\u00eda representar una nueva estrategia para el tratamiento del melanoma y otros tumores s\u00f3lidos, e ImmunoVex, una vacuna para el herpes genital.","og_url":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2011-01-25T23:00:00+00:00","article_modified_time":"2020-11-16T15:15:53+00:00","author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen","datePublished":"2011-01-25T23:00:00+00:00","dateModified":"2020-11-16T15:15:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/"},"wordCount":225,"articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/","url":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/","name":"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"datePublished":"2011-01-25T23:00:00+00:00","dateModified":"2020-11-16T15:15:53+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/ysios-capital-partners-sale-de-biovex-que-ha-sido-adquirida-por-amgen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Ysios Capital Partners sale de Biovex, que ha sido adquirida por Amgen"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/37321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=37321"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/37321\/revisions"}],"predecessor-version":[{"id":43551,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/37321\/revisions\/43551"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=37321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=37321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=37321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}